Please login to the form below

Not currently logged in
Email:
Password:

clopidogrel

This page shows the latest clopidogrel news and features for those working in and with pharma, biotech and healthcare.

Another failed trial knocks back AZ's plan to grow Brilinta

Another failed trial knocks back AZ's plan to grow Brilinta

Brilinta (ticagrelor) was unable to show any improvement over an older generic antiplatelet drug - clopidogrel - in the large-scale EUCLID trial, which enrolled almost 14, 000 people with symptomatic PAD. ... Billed as the largest cardiovascular outcomes

Latest news

  • AZ's Brilinta disappoints in stroke trial AZ's Brilinta disappoints in stroke trial

    superiority to Sanofi's Plavix (clopidogrel), a former blockbuster now subject to generic competition.

  • FDA approval keeps AZ on track with ambitious Brilinta plans FDA approval keeps AZ on track with ambitious Brilinta plans

    Brilinta was previously approved as 90mg tablet given twice-daily after being shown to be superior to clopidogrel in the PLATO trial, and the new indication gives a green light to ... However, it has been suggested the PEGASUS data could also lead to

  • FDA gives the nod to TMC's antiplatelet drug FDA gives the nod to TMC's antiplatelet drug

    into a market formerly dominated by Sanofi's Plavix (clopidogrel) which lost patent protection in 2012. ... The overall occurrence of serious bleeding was low but more common with Kengreal than with clopidogrel, with one in every 170 Kengreal-treated

  • Heart drug sales continue downward spiral Heart drug sales continue downward spiral

    Sanofi has a number of CV medicines including Aprovel (irbesartan), Lovenox (enoxaparin) and the co-marketed Plavix (clopidogrel), which collectively made the firm 4.2bn euro ($4.7bn) last year, helping

  • FDA reviewer backs approval of TMC's cangrelor FDA reviewer backs approval of TMC's cangrelor

    the multibillion-dollar market formerly occupied by Sanofi's Plavix (clopidogrel) which lost patent protection in 2012. ... The FDA now concludes that cangrelor offers a small benefit compared to clopidogrel when used second-line to reduce thrombotic

More from news
Approximately 2 fully matching, plus 97 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Zontivity is a protease-activated receptor-1 antagonist indicated for use in combination with daily aspirin and/or clopidogrel to reduce thrombotic cardiovascular events.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics